Neowise Biotechnology

Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised close to RMB 200 million (USD 29 million) in a Series A+ financing round. This investment will support the company’s ongoing research and development efforts in TCR therapies. Investor ParticipationThe financing round was led by…